Evrópusambandið - íslenska - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane súlfat, tazobactam járn - bakteríusýkingar - sýklalyf fyrir almenn nota, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

leo pharma a/s - takrólímus - dermatitis, atópísk - aðrar húðsjúkdómar - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. koma fjórir eða meira sinnum á ári) sem hafa haft fyrstu viðbrögð við sex vikur meðferð tvisvar á dag takrólímus smyrslið (sár ruddi, næstum ruddi eða dálítið áhrifum).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - lyf til veikindi öndunarvegi sjúkdómum, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

n.v. organon* - montelukastum natríum - tuggutafla - 4 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

recordati ireland ltd. - lídókaín, prilocaine - kynferðisleg truflun, lífeðlisfræðileg - svæfingarlyf - meðferð aðal ótímabært sáðlát í fullorðnum körlum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

recordati ireland ltd - silódósín - blóðflagnafæð - Þvaglát - meðferð á einkennum góðkynja blöðruhálskirtils (bph).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

recordati ireland ltd - silódósín - blóðflagnafæð - urologicals, alfa-adrenoreceptor hemla - meðferð einkenni á góðkynja stækkunar (gÓÐkynja) í fullorðnum körlum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formóteróli fúmarat tvíhýdrat, Þannig brómíð - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

tigenix n.v. - einkennist af raunhæfum sjálfkrafa brjóskum sem stækkuð eru ex vivo sem tjá sértæka próteinprótein - brjóskasjúkdómar - Önnur lyf við sjúkdómum í stoðkerfi - viðgerð á einkennandi brjóskgalla í lærleggsþekju hnésins (international creation repair society [icrs] iii eða iv) hjá fullorðnum. samhliða einkennalaus brjósk sár (icrs bekk ég eða ii) gæti verið til staðar. sönnun á virkni er byggt á slembiraðaði stjórnað prufa að meta verkun chondrocelect í sjúklinga með sár á milli 1 og 5 cm2.